Taiwan’s HORIEN Accelerates Global Footprint: Achieves Three Thai FDA Class 4 Approvals and Secures US Patent for Biodegradable Ureteral Stent
HORIEN Biochemical Technology Co., Ltd. (TW: 7814) today announced a major double milestone in its global expansion strategy: the formal entry into the Thai market following Thai Food and Drug Administration (Thai FDA) Class 4 approvals for three advanced regenerative medical devices, alongside securing a prestigious U.S. invention patent for its innovative biodegradable ureteral stent.
(Press release, 8 September, 2026, PRNewswire)